It's been 100 years since Alzheimer's disease was first described, and yet our best treatments in development for the disease are still highly toxic drugs.
But new research from Rockefeller University, published in the February 26 online edition of Proceedings of the National Academy of Sciences, has identified a therapeutic target, called casein kinase 1, that may be the key to halting the course of the disease. The findings, based on studies in mammalian cells, show that chemicals that block casein kinase 1 don't interfere with a closely connected essential pathway.
Alzheimer's disease is caused by a buildup of a small protein called amyloid-beta, which is formed when a larger protein is broken into pieces. But the enzyme that produces amyloid-beta is also responsible for cleavage of another protein called Notch. The problem with current drugs is that they block these enzymes to stop production of amyloid-beta, and in doing so they also block the cleavage of Notch - which plays an important role in the development of healthy brain cells.
The new research, based on studies by lead author Marc Flajolet and from the Nobel Prize-winning laboratory of Paul Greengard, director of the Fisher Center for Alzheimer's Disease Research at Rockefeller, has identified another protein, casein kinase 1, that controls the regulation of these enzymes. When the researchers block casein kinase 1, production of amyloid-beta proteins goes down, but Notch signaling is not affected.
"Studies of brain tissue from Alzheimer's patients have shown an increase in casein kinase 1 expression," says Greengard, Vincent Astor Professor and head of the Laboratory of Molecular and Cellular Neuroscience. "We found that the key enzymes involved in amyloid-beta production - called BACE and gamma-secretase - were targets of casein kinase 1, so we investigated what role it might be playing."